- Details
- Rashid Sayyid and Zach Klaassen discuss the AUA's updated guidelines for surgical therapy of BPH-related lower urinary tract symptoms. They recommend surgery for patients with complications like renal insufficiency, refractory urinary retention, recurrent UTIs, bladder stones, gross hematuria due to BPH, or when symptoms are unresponsive to other therapies. They note a decrease in TURP surgeries s...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2023 updated AUA guidelines for managing lower urinary tract symptoms (LUTS) attributed to BPH. They focus on evaluating BPH patients, covering initial and follow-up evaluations, pre-operative testing, and treatment failure rates. The initial evaluation includes obtaining a medical history, conducting a physical exam, using the International Prostate Sym...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2023 amended AUA guidelines on advanced prostate cancer. They focus on the epidemiology, early evaluation, and patient counseling. The guidelines, led by Dr. Michael Cookson, form part of a comprehensive six-part series. The discussion highlights the importance of understanding evidence strength, ranging from high-quality randomized trials (Grade A) to st...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the updated AUA guidelines for advanced prostate cancer, focusing on metastatic castration-resistant prostate cancer (mCRPC). The guidelines emphasize the importance of baseline labs, metastatic disease location, and symptoms for prognosis and treatment decisions in mCRPC patients. Statement #25 highlights the significance of various lab markers and metastat...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2023 amended AUA guidelines for advanced prostate cancer, focusing on metastatic hormone-sensitive prostate cancer (mHSPC). They emphasize the importance of assessing metastatic disease extent in newly diagnosed mHSPC patients, as it significantly influences systemic therapy choices. The guidelines recommend using either conventional imaging or PSMA PET...
|
- Details
- Rashid Sayyid and Zach Klaassen explore the AUA guidelines on diagnosing and managing non-metastatic upper tract urothelial carcinoma. Dr. Sayyid outlines the disease's background, emphasizing its rarity and higher risk of advanced presentation compared to bladder urothelial carcinoma. He also covers risk factors like chronic inflammation and Lynch syndrome, and delves into diagnostic procedures s...
|
- Details
- Rashid Sayyid and Zach Klaassen examine the published AUA guidelines for diagnosing and managing non-metastatic upper tract urothelial carcinoma. The conversation spans a wide array of topics including neoadjuvant and adjuvant chemotherapy, immunotherapy, surveillance, and survivorship. Dr. Sayyid focuses on the strong recommendation for cisplatin-based neoadjuvant chemotherapy, especially for hig...
|
- Details
- In a discussion about the published AUA guidelines on non-metastatic upper tract urothelial carcinoma, Rashid Sayyid and Zach Klaassen explore a wide array of treatment options and considerations. Dr. Sayyid focuses on giving patients a comprehensive understanding of both short-term and long-term risks associated with diagnostic and therapeutic choices, including kidney-sparing options like tumor...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the KEYNOTE-B61 trial. This phase II study investigates the efficacy of pembrolizumab plus lenvatinib as a first-line treatment for advanced non-clear cell Renal Cell Carcinoma (RCC). The trial is particularly significant given the limited data and treatment options for non-clear cell RCC, which accounts for about 25% of all RCC cases. The KEYNOTE-B61 trial...
|
